Cargando…

The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification

BACKGROUND: Celastrol, a triterpene present in the traditional Chinese medicine (TCM) Triptergium wilfordii, has been demonstrated to have remarkable anticancer activity. However, its specific mechanism on papillary thyroid carcinoma (PTC) remains to be elucidated. METHODS: Potential targets of cela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Jiaoyu, Tian, Mengran, Hu, Linfei, Kang, Ning, Ma, Weike, Zhi, Jingtai, Zheng, Xiangqian, Ruan, Xianhui, Gao, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184492/ https://www.ncbi.nlm.nih.gov/pubmed/34164500 http://dx.doi.org/10.21037/atm-21-1854

Ejemplares similares

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
por: Hu, Linfei, et al.
Publicado: (2022)

To Explore the Inhibitory Mechanism of Quercetin in Thyroid Papillary Carcinoma through Network Pharmacology and Experiments
por: Sun, Ying, et al.
Publicado: (2022)

Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer
por: Ma, Weike, et al.
Publicado: (2023)

Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes
por: Zhi, Jingtai, et al.
Publicado: (2020)

Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma
por: Zhang, Jun, et al.
Publicado: (2019)

BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients
por: Wu, Yu, et al.
Publicado: (2019)

KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway
por: Zhang, Wei, et al.
Publicado: (2022)

Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer
por: Tang, Tao, et al.
Publicado: (2022)

Identification and validation of eight estrogen-related genes for predicting prognosis of papillary thyroid cancer
por: Zeng, Yu, et al.
Publicado: (2023)

Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents
por: Huang, Dongmei, et al.
Publicado: (2022)

Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma
por: Gu, Pengfei, et al.
Publicado: (2022)

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis
por: Jingtai, Zhi, et al.
Publicado: (2023)

Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway
por: Zhao, Zewei, et al.
Publicado: (2022)

Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study
por: Wang, Huijuan, et al.
Publicado: (2020)

Consistent analysis of differentially expressed genes across 7 cell types in papillary thyroid carcinoma
por: Ruan, Xianhui, et al.
Publicado: (2023)

Comprehensive analysis of PPPCs family reveals the clinical significance of PPP1CA and PPP4C in breast cancer
por: Xie, Wenjun, et al.
Publicado: (2021)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma
por: Hou, Xiukun, et al.
Publicado: (2021)

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
por: Zhi, Jingtai, et al.
Publicado: (2017)

Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles
por: Wei, Songfeng, et al.
Publicado: (2019)

High expression of NUCB2 promotes papillary thyroid cancer cells proliferation and invasion
por: Zhao, Jingzhu, et al.
Publicado: (2019)

FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer
por: Qiu, Li, et al.
Publicado: (2020)

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
por: Zheng, Xiangqian, et al.
Publicado: (2019)

PARP inhibitor shuts down the global translation of thyroid cancer through promoting Pol II binding to DIMT1 pause
por: Hou, Xiukun, et al.
Publicado: (2023)

Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer
por: Zhang, Jun, et al.
Publicado: (2021)

Autophagy in the pharmacological activities of celastrol (Review)
por: Zhang, Caixia, et al.
Publicado: (2023)

Untargeted lipidomic analysis and network pharmacology for parthenolide treated papillary thyroid carcinoma cells
por: Huang, Le-Tian, et al.
Publicado: (2023)

Indoleamine 2,3-dioxygenase 2 immunohistochemical expression in medullary thyroid carcinoma: implications in prognosis and immunomodulatory effects
por: Gu, Pengfei, et al.
Publicado: (2022)

Investigation of the mechanism of Prunella vulgaris in treatment of papillary thyroid carcinoma based on network pharmacology integrated molecular docking and experimental verification
por: Zhu, Xiling, et al.
Publicado: (2023)

Active surveillance as a management strategy for papillary thyroid microcarcinoma
por: Zhang, Huan, et al.
Publicado: (2020)

Diagnosis and treatment of ectopic thyroid carcinoma: A case report and literature review
por: Fu, Guiming, et al.
Publicado: (2022)

Identifying the Effect of Celastrol Against Ovarian Cancer With Network Pharmacology and In Vitro Experiments
por: Wang, Xuan, et al.
Publicado: (2022)

Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes
por: Wu, Ming, et al.
Publicado: (2022)

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids
por: Wang, Huabo, et al.
Publicado: (2015)

Systematic identification of Celastrol-binding proteins reveals that Shoc2 is inhibited by Celastrol
por: Xiao-pei, Huang, et al.
Publicado: (2018)

Integrated microRNA-mRNA analyses of distinct expression profiles in follicular thyroid tumors
por: Chi, Jiadong, et al.
Publicado: (2017)

Investigating Celastrol's Anti-DCM Targets and Mechanisms via Network Pharmacology and Experimental Validation
por: Xi, Rui, et al.
Publicado: (2022)

Celastrol-conjugated chitosan oligosaccharide for the treatment of pancreatic cancer
por: Zeng, Xiaohu, et al.
Publicado: (2021)

Correction: Systematic identification of celastrol-binding proteins reveals that Shoc2 is inhibited by celastrol
Publicado: (2021)

Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats
por: Cascão, Rita, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lp2qm91j3pbq0bj49ac5mnt7g7